Mobley et al., 1988 - Google Patents
Nerve growth factor increases mRNA levels for the prion protein and the beta-amyloid protein precursor in developing hamster brain.Mobley et al., 1988
View PDF- Document ID
- 14136356288593332677
- Author
- Mobley W
- Neve R
- Prusiner S
- McKinley M
- Publication year
- Publication venue
- Proceedings of the National Academy of Sciences
External Links
Snippet
Deposition of amyloid filaments serves as a pathologic hallmark for some neurodegenerative disorders. The prion protein (PrP) is found in amyloid of animals with scrapie and humans with Creutzfeldt-Jakob disease; the beta protein is present in amyloid …
- 108091000054 Prion Proteins 0 title abstract description 95
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mobley et al. | Nerve growth factor increases mRNA levels for the prion protein and the beta-amyloid protein precursor in developing hamster brain. | |
| Scott et al. | Nerve growth factor and Alzheimer's disease | |
| Iacopino et al. | Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. | |
| Vulih-Shultzman et al. | Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model | |
| Geula et al. | Amyloid-β deposits in the cerebral cortex of the aged common marmoset (Callithrix jacchus): incidence and chemical composition | |
| Mann et al. | The noradrenergic system in Alzheimer and multi-infarct dementias. | |
| Forloni et al. | Expression of amyloid precursor protein mRNAs in endothelial, neuronal and glial cells: modulation by interleukin-1 | |
| Kramer et al. | Induction of metallothionein mRNA and protein in murine astrocyte cultures | |
| Gearing et al. | Neuropathology and apolipoprotein E profile of aged chimpanzees: implications for Alzheimer disease. | |
| Spreyer et al. | Regeneration‐associated high level expression of apolipoprotein D mRNA in endoneurial fibroblasts of peripheral nerve. | |
| Flanders et al. | Altered expression of transforming growth factor-beta in Alzheimer's disease | |
| Holsinger et al. | Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer's disease | |
| Murray et al. | Differential regulation of brain-derived neurotrophic factor and type II calcium/calmodulin-dependent protein kinase messenger RNA expression in Alzheimer's disease | |
| Rousselet et al. | Role of TNF-α receptors in mice intoxicated with the parkinsonian toxin MPTP | |
| US20220062389A1 (en) | Methods for the identification, assessment, prevention, and treatment of neurological disorders and diseases using fndc5 | |
| JP2004091492A (en) | Amyloid beta protein (globular assembly and use thereof) | |
| Mufson et al. | Apolipoprotein E-immunoreactivity in aged rhesus monkey cortex: colocalization with amyloid plaques | |
| Münch et al. | Advanced glycation endproducts and pro‐inflammatory cytokines in transgenic Tg2576 mice with amyloid plaque pathology | |
| KR20000075748A (en) | Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease | |
| Ali et al. | Induction of apolipoprotein E mRNA in the hippocampus of the gerbil after transient global ischemia | |
| Copray et al. | Contraction-induced muscle fiber damage is increased in soleus muscle of streptozotocin-diabetic rats and is associated with elevated expression of brain-derived neurotrophic factor mRNA in muscle fibers and activated satellite cells | |
| Leveugle et al. | Proteoglycans and the acute-phase response in Alzheimer's disease brain | |
| Rousseaux et al. | “Shaker” calf syndrome: a newly recognized inherited neurodegenerative disorder of horned Hereford calves | |
| Johnston et al. | The significance of the Swedish APP670/671 mutation for the development of Alzheimer's disease amyloidosis | |
| McKinley et al. | Nerve growth factor induces gene expression of the prion protein and βbT-amyloid protein precursor in the developing hamster central nervous system |